Immune globulin (human) is under clinical development by CSL and currently in Phase III for Chronic Lymphocytic Leukemia (CLL).
Passive anti-D immune globulin administered to prevent anti ... D antibody in the maternal plasma Serial two-fold dilutions of serum are prepared and tested for antibody activity and the highest ...
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia ...
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia ...
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA ® [Immune Globulin Infusion 10% (Human) with Recombinant Human ...
Hoyee Leong, PH.D.; Joan Stachnik, Pharm.D.; Mary Ellen Bonk, Pharm.D.; Karl A. Matuszewski, M.S., Pharm.D.
BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr ...
Immunology is the branch of biomedical sciences concerned with all aspects of the immune system in all multicellular organisms. Systemic lupus erythematosus (SLE) is an autoimmune disease with ...